Exact Sciences Valuation
Is EXAS * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of EXAS * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: EXAS * (MX$872) is trading below our estimate of fair value (MX$2100.19)
Significantly Below Fair Value: EXAS * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EXAS *?
Key metric: As EXAS * is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is EXAS *'s PS Ratio? | |
|---|---|
| PS Ratio | 5x |
| Sales | US$2.61b |
| Market Cap | US$13.11b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.7x |
| Enterprise Value/EBITDA | -217x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does EXAS *'s PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 12.5x | ||
BMRN BioMarin Pharmaceutical | 4.4x | 7.7% | US$12.1b |
INSM Insmed | 38.2x | 49.4% | US$13.2b |
INCY Incyte | 3.4x | 8.9% | US$13.6b |
SOBI Swedish Orphan Biovitrum | 3.9x | 9.0% | SEK 99.6b |
EXAS * Exact Sciences | 5x | 11.1% | Mex$13.1b |
Price-To-Sales vs Peers: EXAS * is good value based on its Price-To-Sales Ratio (5x) compared to the peer average (13.4x).
Price to Sales Ratio vs Industry
How does EXAS *'s PS Ratio compare vs other companies in the Global Biotechs Industry?
| 278 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 278 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: EXAS * is good value based on its Price-To-Sales Ratio (5x) compared to the Global Biotechs industry average (10.2x).
Price to Sales Ratio vs Fair Ratio
What is EXAS *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 5x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate EXAS *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
IQVIA Holdings
US$35.9b
Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
IQV *
US$3,880.00
7D
-11.8%
1Y
12.0%
ICON
US$17.6b
A clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.
ICLR N
US$4,286.08
7D
0%
1Y
-7.7%
Laboratorios Farmaceuticos Rovi
€3.2b
Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.
ROVI N
€1,416.38
7D
0%
1Y
54.7%